Introduction
Over the past 20 years, strong evidence has con®rmed that endothelial cells (EC) represent a metabolically active tissue rather than a simple barrier between blood and interstitial uid. The pluripotent ability of these cells allows them to respond to a wide range of stimuli known to play a critical role not only in the balance of vascular tone and permeability, but also in the pathogenesis of certain diseases such as tumor growth, diabetic retinopathy as well as psoriasis (Folkman, 1991; Folkman & Klagsbrun, 1997) . Aberrant angiogenesis, characterized by uncontrolled growth of new capillaries from pre-existing blood vessels, has been found to be a crucial component of these pathologies (Folkman & Klagsbrun, 1997) .
Several reports suggest that in¯ammation regularly and perhaps invariably precedes and/or accompanies angiogenesis (Jackson et al., 1997; . Blood vessels in and around tumours display increased vascular permeability (Dvorak et al., 1988) and in¯ammatory monocytes/macrophages can be found at sites where angiogenesis is occurring in an abnormal environment (Sunderkotter et al., 1994) . One likely candidate for the regulation of pathological angiogenesis is the vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) (Ferrara, 1995) . This is suggested in part by observations that high levels of VEGF are produced by various types of tumours (Kondo et al., 1994) , and that tumour growth is attenuated in vivo by anti-VEGF antibodies (Kim et al., 1993) . Although many growth factors such as VEGF can induce endothelial cell (EC) migration and proliferation in culture, VEGF is the only one capable of enhancing vascular permeability (Connolly et al., 1989; Folkman & Klagsbrun, 1997) , and it is likely that its angiogenic properties are mediated in part by its ability to modulate¯uid and protein extravasation. We have recently reported that VEGF-induced protein extravasation in vivo was abolished by a pretreatment with a selective plateletactivating factor (PAF) receptor antagonist, suggesting that VEGF eect on vascular permeability was mediated through PAF synthesis (Sirois & Edelman, 1997) . This hypothesis was supported by the rapid induction of PAF synthesis in cultured bovine aortic endothelial cells (BAEC) treated with VEGF. In addition, we showed that VEGF eect on BAEC migration, proliferation and PAF synthesis was dependent on the activation of the receptor encoded by the Flk-1/KDR gene (Bernatchez et al., 1999) . However, the intracellular events related to VEGF-induced PAF production remain unknown.
Two synthetic pathways for PAF synthesis have been described. One route, de novo synthesis, is thought to produce constitutively a small amount of PAF in tissues, which allows ecient homeostasis between the bloodstream and interstitial uid (Venable et al., 1993) . The dominant in¯ammatory mechanism of PAF biosynthesis in EC is thought to occur through a two step remodelling pathway where the acyl moiety of alkylacylglycerophosphorylcholine, a membrane-associated phospholipid, is initially removed by either the direct action of a phospholipase A 2 (PLA 2 ) or by a CoA-independent transacylase (CoA-IT) to form lyso-PAF. The ®nal step, the acetylation of the lyso-PAF, is catalyzed by the acetylCoA:-lyso-PAF acetyltransferase (lyso-PAF-AT) leading to PAF synthesis (Bussolino & Camussi, 1995; Snyder et al., 1996) .
Several in¯ammatory mediators were shown to directly induce the activation of the remodelling route, leading to very-early, early and delayed PAF synthesis (Bussolino & Camussi, 1995) . However, there are no data regarding the capacity of growth factors to activate this pathway. Consequently, we sought to determine whether the elevation of PAF synthesis elicited by VEGF might be related to an increased activity of the remodelling pathway. 
Methods

Drugs
Cell culture
BAEC and human umbilical vein endothelial cells (HUVEC) were isolated from freshly harvested aorta or umbilical cords respectively, and cultured and characterized as described previously (Sirois & Edelman, 1997; Bernatchez et al., 1999) . BAEC and HUVEC were not passaged for more than 10 and ®ve passages respectively.
Measurement of PAF synthesis
PAF production by BAEC and HUVEC was measured by incorporation of 3 H-acetate into lyso-PAF (Sirois & Edelman, 1997; Bernatchez et al., 1999) . Con¯uent BAEC or HUVEC (6-well tissue culture plate) were rinsed with HBSS (Hank's balanced salt solution)/HEPES (10 mM; pH 7.4). Cells were then stimulated for 15 min in 1 ml of HBSS-HEPES (10 mM, pH 7.4)+CaCl 2 (0 ± 10 mM)+ 3 H-acetate (25 mCi) plus the appropriate concentration of VEGF. Inhibitors were added 5 to 30 min prior to the addition of VEGF (1 nM). The reaction was stopped by addition of acidi®ed methanol (50 mM acetic acid), the wells were scraped and added to chloroform (2.5 ml) and 0.1 M sodium acetate (1 ml) mixture. Culture plates were washed twice with 1 ml of methanol, added to the chloroform mixture, shaken vigorously and centrifuged for 2 min at 1700 r.p.m. The upper phase was discarded and the chloroform phase was washed twice with 2 ml of the organic phase of a HBSS-HEPES (10 mM)-methanol-chloroform-sodium acetate (0.1 M) solution (1 : 2.5 : 3.75 : 1). Isolated lipids were evaporated under a stream of N 2 gas, resuspended in 175 ml of mobile phase solvent (water-chloroform-methanol 5 : 40 : 55) and puri®ed by a silica-based normal-phase HPLC column (4.56250 mm, 5 mm silica particle size; Varian, Harbour City, CA, U.S.A.) and eluted with the mobile phase solvent at a 0.5 ml min Western blot analysis of secreted phospholipases A 2 expression Con¯uent BAEC and HUVEC (100 mm tissue culture plate) were rinsed with HBSS-HEPES (10 mM; pH 7.4). Cells were then stimulated for 15 min in 3 ml of HBSS-HEPES (10 mM, pH 7.4)+CaCl 2 (10 mM)+acetate (6 nM) with or without VEGF (1 nM). The supernatants and the cells were collected. Total proteins were isolated by the addition of 500 ml of lysis buer with PMSF 1 mM (Sigma), leupeptin 10 mg ml 71 (Sigma), aprotinin 30 mg ml 71 (Sigma) and NaVO 3 1 mM (Sigma). Plates were scraped using a plastic policeman and the protein concentration was determined with a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, U.S.A.). Total protein (40 mg) was separated by a 10% tricine SDS ± PAGE gel (Novex) and transblotted onto a Immobilon-P PVDF membrane (Millipore, Bedford, MA, U.S.A.). Membranes were blocked in immunoblot buer (mM:Tris-HCl 10 (pH 8.0), EDTA 1, NaCl 150, 0.1% Triton X-100) with 5% bovine serum albumin and 5% nonfat dry milk for 1 h at room temperature with gentle agitation. Membranes were then incubated for 1 h in Immunoblot buer containing 1% Bovine Serum Albumin and 1% nonfat dry milk with sPLA 2 (human synovial) polyclonal antiserum (dilution 1 : 4000, Cayman Chemical) which recognizes both group IIA and group V PLA 2 . Membranes were washed three times with Immunoblot buer and incubated with biotinylated goat anti-rabbit IgG antibodies (dilution 1 : 10,000, Vector Laboratories, Burlingame, CA, U.S.A.) for 30 min. Membranes were washed three times with Immunoblot buer and incubated with horseradish peroxidase streptavidin (dilution 1 : 10,000, Vector Laboratories) for 30 min. Membranes were washed with immunoblot buer and horseradish peroxidase was revealed by chemiluminesence (ECL kit, Amersham). Human synovial¯uid group IIA sPLA 2 (Cayman Chemicals) and P388D1 macrophage cell lysate were used as positive controls. Kaleidoscope molecular weight marker proteins were used as standards for SDS ± PAGE.
Reverse transcriptase-polymerase chain reaction analysis of group IIA and V sPLA 2 gene expression Total RNA from BAEC and HUVEC was prepared using the Trizol reagent system (Life Technologies, Grand Island, NY, U.S.A.). Total RNA from human brain, heart and intestine was from Clonetech (Palo Alto, CA, U.S.A.). Single strand cDNA was synthesized in a reaction that contained 2 mg of total RNA with 0.5 mg random hexamers (Amersham Pharmacia, Uppsala, Sweden) and 200 units M-MLV reverse transcriptase (Promega, Madison, WI, U.S.A.) at 378C for 1 h. 0.3 mg of cDNA was then utilized for PCR using Taq DNA polymerase (Promega). Reaction conditions were as follows: denature at 948C for 40 s, anneal at 508C for 1 min, extend at 728C for 1 min for 30 cycles. The primers used to amplify group IIA sPLA 2 were designed using the human sequence: 5'-CTT ACC ATG AAG ACC CTC CTA CTG TTG GCA-3' and 5'-GAG GGG ACT CAG CAA CGA GGG GTG CT-3'. Primers for group V sPLA 2 were from highly conserved regions of the human and mouse sequences: 5'-GGC TTC TAC GGC TGT TAC TG-3' and 5'-GTA GAC GAG CTT CCG GTC AC-3'.
Statistical analysis
Data are mean+s.e.mean. Statistical comparisons were made by analysis of variance followed by an unpaired Student's ttest. Data were considered signi®cantly dierent if values of P50.05 were observed.
Results
Induction of endothelial cell PAF synthesis by VEGF is [Ca 2+ ]-dependent
We recently reported that VEGF dose-dependently induced the synthesis of PAF in BAEC (Sirois & Edelman, 1997; Bernatchez et al., 1999) . However, these experiments were performed exclusively in the presence of high extracellular Ca 2+ concentration (10 mM). In the present study we assessed the contribution of extracellular Ca 2+ for the induction of EC PAF production mediated by VEGF on BAEC. In the presence of 10 mM CaCl 2 , VEGF (1 nM) induced an increase in PAF synthesis which was considered maximal (100%) as compared to control buer (0%) (Figure 1 ). However, when BAEC were incubated in the absence of extracellular CaCl 2 (0 mM) or CaCl 2 (0 mM)+EDTA (1 mM), VEGF failed to signi®cantly increase the basal production of PAF by EC. We then sought to determine the Ca 2+ concentration required by the BAEC to synthesize PAF in response to VEGF. Although an increase of CaCl 2 to 1 and 10 mM concentrations did not modulate the basal PAF production, the application of CaCl 2 to 100 mM and 1 mM induced a signi®cant increase of PAF synthesis, which represented 1.2 and 67% of the maximal amount of PAF synthesized by BAEC when stimulated with VEGF (1 nM) in the presence of 10 mM CaCl 2 . As a result, the subsequent experiments were performed in the presence of 10 mM CaCl 2 .
The effect of VEGF on EC PAF synthesis is attenuated by remodelling pathway and group V sPLA 2 inhibitors
Since growing evidence indicates that the remodelling route is activated during in¯ammation and other hypersensitivity responses, we used a range of speci®c inhibitors of the aforementioned pathway to determine its possible involvement in VEGF-induced PAF production in EC from two dierent sources, namely BAEC and HUVEC ( Figure 2 ). First, VEGF (1 nM) increased by 28 and 4 fold the basal production of PAF by BAEC and HUVEC as compared to PBS control buer (P50.001), respectively ( Figure 3A,B) . The addition of a potent inhibitor of both the lyso-PAF-AT and the CoA-IT activities (Sanguinarin; 500 nM) (Snyder et al., 1996) blocked the amount of PAF synthesized by BAEC and HUVEC by 95 and 97%, respectively, in response to VEGF treatment (1 nM) ( Figure 3A,B) . In contrast, a pretreatment with a selective CoA-IT inhibitor (SKF45905; 10 ± 50 mM; IC 50 =6 mM) (Winkler et al., 1996a) did not ). Fractions were collected every min after injection and radioactivity was determined with a b-counter. The values are means of at least six experiments. *P50.05 and ***P50.001 as compared to control buer (PBS) as determined by analysis of variance followed by an unpaired Student's t-test.
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Considering that PLA 2 were also shown to be capable of mediating the production of lyso-PAF, we used a variety of PLA 2 inhibitors. First, a pretreatment with a competitive inhibitor of the group IV 85 kDa cytosolic PLA 2 (cPLA 2 ) and group VI Ca 2+ -independent PLA 2 (iPLA 2 ) (AACOCF 3 ; 10 ± 50 mM; IC 50 =100 nM for human recombinant cPLA 2 and 15 mM for semi-puri®ed iPLA 2 ) (Ackermann et al., 1995) did not reduce VEGF-induced EC PAF synthesis. In contrast, a potent irreversible inhibitor of both the cPLA 2 and iPLA 2 (MAFP; 10 mM; IC 50 =600 nM for recombinant cPLA 2 and 500 nM for iPLA 2 ) (Leslie, 1997; Fujishima et al., 1999) increased VEGF eect on BAEC and HUVEC PAF synthesis by 126 and 531%, respectively ( Figure 3A,B) . Interestingly, a speci®c inhibitor of the group VI iPLA 2 (BEL; 10 mM; IC 50 =60 nM) (Ackermann et al., 1995) also potentiated VEGF eect, elevating PAF biosynthesis by 113 and 129% in BAEC and HUVEC respectively ( Figure 3A,B) . These results clearly show that both cPLA 2 and iPLA 2 activity are not directly involved in EC PAF synthesis upon VEGF stimulation as their inhibition did not prevent PAF synthesis. In contrast, a broad-range 14 kDa sPLA 2 inhibitor (Scalaradial; 10 mM) (de Carvalho & Jacobs, 1991; Marshall et al., 1994; which has been shown to block several sPLA 2 s attenuated by 87 and 73% the synthesis of PAF mediated by VEGF in BAEC and HUVEC respectively, thereby suggesting that this biological response is initiated by a sPLA 2 . Furthermore, the use of a speci®c group IIA and V sPLA 2 inhibitor (SB203347; 10 mM; IC 50 =500 nM) (Marshall et al., 1995) blocked by 90% VEGF eect on both EC types ( Figure  3A,B) . Interestingly, the use of a structurally designed sPLA 2 inhibitor (LY311727) at a concentration known to block speci®cally group IIA sPLA 2 (1 mM; IC 50 =51 mM for group IIA sPLA 2 ) (Murakami et al., 1998) did not have any eect as well on PAF synthesis induced by VEGF, whereas it attenuated by 62 and 81% the synthesis of PAF in BAEC and HUVEC, respectively, when used at a concentration reported to block both groups IIA and V sPLA 2 (100 mM; IC 50 =450 mM for group V sPLA 2 ) ( Figure 3A ,B) (Murakami et al., 1998) .
BAEC and HUVEC express group V but not group IIA sPLA 2
Considering that the addition of SB203347 (10 mM) and LY311727 (100 mM) attenuated PAF biosynthesis, we attempted to determine if BAEC and HUVEC express either group IIA and/or group V sPLA 2 . Con¯uent cells were stimulated with VEGF (1 nM) for 15 min, the supernatants and the cells were collected, the proteins were separated by SDS ± PAGE and a Western blot analysis was performed with the use of an anti-human sPLA 2 antibody which recognizes both group IIA and V sPLA 2 . Human synovial sPLA 2 (group IIA sPLA 2 positive control) and P388D1 (group V sPLA 2 positive control) (Balboa et al., 1996) presented a dierent migration pattern from each other (Figure 4) . Interestingly, the application of 40 mg of BAEC and HUVEC protein extracts that were stimulated with Figure 2 Biosynthesis of lyso-PAF and PAF via the remodelling pathway. The initial hydrolysis of the acyl moiety of alkylacylglycerophosphocholine to form lyso-PAF and arachidonic acid (AA) can be catalyzed by the action of a direct phospholipase A 2 (PLA 2 ) or a CoA-independent transacylase (CoA-IT). Lyso-plasmalogen and other lyso-glycerophospholipids can act as the acyl acceptor in the CoA-independent transacylase type of reaction. The lyso-PAF is then converted to PAF by the acetylCoA:lyso-PAF acetyltransferase. Above, are the names of selective inhibitors used to identify the enzymes involved in VEGFmediated PAF synthesis upon remodelling pathway activation. R=(CH 2 ) n -CH 3 where n=15 to 17 and R'=(CH 2 ) 2 N + (CH 3 ) 3 .
British Journal of Pharmacology vol 134 (1) VEGF induces PAF synthesis through sPLA 2 activation P.N. Bernatchez et alVEGF revealed that both EC types express group V sPLA 2 , whereas group IIA sPLA 2 expression was not detected (Figure 4) . In another experiment, we have observed a constitutive endogenous expression of group V sPLA 2 in non-treated BAEC and HUVEC (data not shown). This enzyme remained cell-associated as we did not detect the presence of group V or group IIA sPLA 2 in the supernatant of BAEC and HUVEC treated or not with VEGF (1 nM) for 15 min (data not shown).
HUVEC express group V but not group IIA sPLA 2 mRNA
Since the data presented in Figure 4 demonstrate the presence of group V sPLA 2 and the absence of group IIA sPLA 2 in both BAEC and HUVEC, we then sought to con®rm by RT ± PCR if these two EC types synthesize constitutively group IIA and V sPLA 2 mRNA. This approach allows a far more speci®c and sensitive analysis of the group IIA and V sPLA 2 gene expression. The present RT ± PCR experiments con®rmed the presence of group IIA sPLA 2 mRNA in human intestine RNA extracts (positive control), its absence in human brain RNA extracts (negative control) (450 base-pairs; Figure 5A ) and the presence of group V sPLA 2 in human brain and heart RNA extracts (positive controls) (225 base-pairs; Figure 5B ). Interestingly, group IIA sPLA 2 was not detected in both stimulated and non-stimulated BAEC and HUVEC ( Figure  5A ), whereas group V sPLA 2 was detected in stimulated and non-stimulated HUVEC but not in BAEC ( Figure 5B ). As the bovine group V sPLA 2 cDNA sequence is still unknown, we may hypothesize that this enzyme has not been detected in BAEC by RT ± PCR because of possible mismatches between the human and mouse oligonucleotides used in these experiments, and the bovine group V sPLA 2 cDNA sequences.
Discussion
Vascular endothelial growth factor, unlike any other growth factors studied to date, is capable of inducing protein extravasation and it is likely that its angiogenic properties are mediated in large part through the induction of plasma protein leakage (Dvorak et al., 1988; Connolly et al., 1989) . In the present study, we report that VEGF induces PAF synthesis by EC through the action of sPLA 2 , most likely group V sPLA 2 . These ®ndings not only shed light on the intracellular events initiated by VEGF on the vascular endothelium, but also may enable rational interventions to regulate vascular diseases such as in¯ammation and possibly uncontrolled angiogenesis attributable to VEGF overexpression. Figure 3 Eect of the remodelling pathway inhibitors on VEGFinduced PAF synthesis. (A) Con¯uent BAEC (6-well tissue culture plate) were pretreated 5 or 30 min with the remodelling pathway inhibitors Sanguinarine (Sang; 500 mM), SKF45905 (SKF; up to 50 mM), AACOCF 3 (AACOCF 3 ; 50 mM), MAFP (MAFP; 10 mM), BEL (BEL; 10 mM), Scalaradial (Scal; 10 mM), SB203347 (SB; 10 mM) and LY311727 (LY; up to 100 mM) stimulated with VEGF (1 nM)+ 3 H-acetate+10 mM CaCl 2 , and the lipids were extracted and puri®ed as described in Figure 1 . The values are means of at least four experiments. (B) Con¯uent HUVEC were treated as described for BAEC. *P50.05 and ***P50.001 as compared to control buer (PBS), and {P50.05, {{P50.01, {{{P50.001 as compared to VEGF (1 nM) as determined by analysis of variance followed by an unpaired Student's t-test. Figure 4 Expression of group IIA and V sPLA 2 by BAEC and HUVEC. Con¯uent BAEC and HUVEC (100 mm tissue culture plate) were rinsed and stimulated with VEGF (1 nM) for 15 min. Cells were scraped and total proteins were isolated. Forty mg of crude proteins were separated by a 10% SDS ± PAGE and transblotted onto a PVDF membrane. Proteins were detected by a sPLA 2 (human synovial) polyclonal antiserum which recognizes both group IIA and group V sPLA 2 . Lane 1: P388D1 macrophage cell lysate (group V sPLA 2 positive control). Lane 2: Human synovial¯uid sPLA 2 (group IIA sPLA 2 positive control). Lane 3: BAEC lysate. Lane 4: HUVEC lysate.
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VEGF increased EC PAF synthesis in vitro
In a previous report we showed for the ®rst time the eect of VEGF on mediating PAF synthesis in BAEC (Sirois & Edelman, 1997) . More recently, others have con®rmed the capacity of VEGF to elicit PAF synthesis in HUVEC (Montrucchio et al., 2000) . It is of interest to note that BAEC are far more potent than HUVEC to synthesize PAF in response to VEGF. This observation is supported by previous studies that have shown that venous endothelial cells produce far less PAF as compared to arterial cells (Whatley et al., 1988) . Thus, this dierence of response to VEGF is most likely not attributable to dierences in VEGF activity on BAEC and HUVEC, but rather to dierences between the capacity of the enzymes to synthesize PAF in these two EC types.
VEGF stimulated the remodelling pathway through the action of group V sPLA 2 Micromolar (mM) calcium levels are known to be a crucial cofactor for a wide range of intracellular events (Chakravarthy et al., 1999) . However, our results showed that an extracellular millimolar (mM) Ca 2+ concentration is required to fully elicit PAF synthesis. These results are in accordance with previous studies that showed that maximal BAEC PAF synthesis is directly dependent on millimolar extracellular Ca 2+ concentration (Whatley et al., 1989) . These authors furthermore demonstrated that this important Ca 2+ requirement is attributable to the PLA 2 -mediated conversion of membrane phospholipids into lyso-PAF induced by various pro-in¯ammatory stimuli. Interestingly, the Ca 2+ -concentration dependence of enzymatic activity is one of the major de®ning characteristics for 14 kDa sPLA 2 s, since they were reported to bind millimolar Ca 2+ within a highly conserved calcium binding loop in order to stabilize the transition state of the phospholipid substrate (Dennis, 1994; Tish®eld, 1997) . Hence, our results demonstrate that biosynthesis of PAF in BAEC through Flk-1/KDR tyrosine kinase receptor activation by VEGF is at least in part similar to the one observed following activation of G protein-coupled receptors and raise the possibility that sPLA 2 may participate in mediating VEGF-induced EC PAF synthesis.
Sanguinarin has previously been shown to have a high degree of selectivity towards the inhibition of both the lyso-PAF-AT and CoA-IT activities (Snyder et al., 1996) . Therefore, this inhibitor should be a valuable tool to assess the possible involvement of the remodelling pathway in numerous cellular events. Pretreatment of BAEC and HUVEC with Sanguinarin almost completely abolished the synthesis of PAF induced by VEGF, suggesting that VEGF is capable of inducing the activation of the remodelling pathway. To the best of our knowledge, these data are the ®rst to show that a growth factor can mediate such activity, and also con®rm that the remodelling route is in¯uenced by proin¯ammatory stimuli.
A possible key player in the synthesis of PAF through the remodelling pathway is the CoA-IT. This enzyme transfers an sn-2 acyl group from a diacylglycerophosphatide to a lysophospholipid in the presence or absence of Coenzyme A (Snyder et al., 1992; Winkler et al., 1996a) . However, a pretreatment with a speci®c CoA-IT inhibitor (SKF45905) (Winkler et al., 1996a) did not attenuate PAF synthesis in both EC types. This observation is in accordance with previous reports indicating that EC contain far less CoA-IT activity than in¯ammatory cells such as neutrophils and monocytes (Winkler & Chilton, 1995; Winkler et al., 1996b) . Taken together, these observations demonstrate that the CoA-IT is unlikely to take part in EC lyso-PAF synthesis mediated by VEGF and suggest that lyso-PAF synthesis is initiated through the activation of a sPLA 2 . This hypothesis is relevant since others have shown that VEGF could promote the synthesis of prostaglandins in EC, which is recognized as a marker of PLA 2 activity (Murohara et al., 1998) .
Phospholipases A 2 consist of a growing superfamily of enzymes, also capable of hydrolyzing membrane phospholipids with the concomitant production of lyso-phospholipids (Dennis, 1994; Tish®eld, 1997) . Though some of these enzymes are very unlikely to play a role in VEGF-induced PAF synthesis by BAEC, others may be directly involved in EC PAF synthesis. Since our results support that Ca 2+ is a crucial cofactor for VEGF-induced PAF production by EC, likely candidates for mediating such activity are the groups IIA and V sPLA 2 . Nonetheless, the possible eects of other recently described sPLA 2 (groups IID, IIE, IIF and X) cannot be ruled out (Six & Dennis, 2000) , despite the fact that their expression have not been reported in EC yet.
Hence, we used dierent inhibitors of the groups IIA and V sPLA 2 . A pretreatment with a non-speci®c 14 kDa sPLA 2 inhibitor (Scalaradial) previously reported to block several sPLA 2 s including group IIA and most probably group V sPLA 2 (de Carvalho & Jacobs, 1991; Marshall et al., 1994; blocked almost completely EC PAF synthesis. Moreover, an inhibitor of both groups IIA and V sPLA 2 (SB203347) (Marshall et al., 1995) which possess a 40 fold speci®city for groups IIA and V sPLA 2 over group IV 85 kDa cPLA 2 abrogated almost completely VEGF-induced EC PAF synthesis. In contrast, treatment with LY311727 (1 mM), another well-described sPLA 2 inhibitor which at such Figure 5 Expression of group IIA and V sPLA 2 mRNA by BAEC and HUVEC. Con¯uent BAEC and HUVEC were lysed, total RNA was extracted and used for RT ± PCR. The sizes of the expected ampli®ed fragments are 450 base-pairs for group IIA sPLA 2 (A) and 225 base-pairs for group V sPLA 2 (B). Human brain and intestine mRNA were used as negative and positive controls respectively, for group IIA sPLA 2 RT ± PCR (A). Human brain and human heart mRNA were used as positive controls for group V sPLA 2 RT ± PCR (B).
British Journal of Pharmacology vol 134 (1) VEGF induces PAF synthesis through sPLA 2 activation P.N. Bernatchez et alconcentration blocks group IIA sPLA 2 activity, did not signi®cantly aect VEGF induction of PAF synthesis in both BAEC in HUVEC. However, when used at a concentration reported to block both groups IIA and V sPLA 2 (100 mM) (Murakami et al., 1998) , LY311727 inhibited signi®cantly VEGF-induced PAF synthesis. Taken together, these results demonstrate that group V sPLA 2 is responsible for the synthesis of lyso-PAF induced by VEGF. Interestingly, several pieces of evidence support such hypothesis. Others have reported that group V sPLA 2 can catalyze more eciently the hydrolysis of phospholipid bilayers than group IIA sPLA 2 , liberating arachidonic acid and lyso-phospholipids, while group IIA sPLA 2 appears to have a relatively low anity for membrane phospholipids (Han et al., 1998) .
Group IV cPLA 2 and group VI iPLA 2 are two cellassociated phospholipases both capable of in¯uencing cellular fatty acid metabolism by increasing free arachidonic acid levels Leslie, 1997) . Thus, these two enzymes could possibly be linked to the synthesis of lyso-PAF from membrane phospholipids initiated by VEGF. A speci®c inhibitor of both the group IV cPLA 2 and VI iPLA 2 (AACOCF 3 ) (Ackermann et al., 1995 , McNicol & Nickolaychuk, 1995 Leslie, 1997; Fujishima et al., 1999) did not signi®cantly modulate PAF synthesis induced by VEGF. In contrast, an irreversible inhibitor of both the cPLA 2 and iPLA 2 with a greater eect on iPLA 2 than cPLA 2 (MAFP) (Leslie, 1997; Fujishima et al., 1999) greatly potentiated VEGF eect. Moreover, a speci®c iPLA 2 inhibitor (BEL) also increased the synthesis of PAF induced by VEGF in BAEC and HUVEC. Thus, this clearly demonstrates that cPLA 2 and iPLA 2 are not directly involved in EC lyso-PAF biosynthesis induced by VEGF, and that iPLA 2 inhibition by either BEL or MAFP potentiates VEGF eect on EC PAF synthesis. This furthermore suggests that group VI iPLA 2 may hydrolyze similar membrane phospholipids to the ones required to mediate EC PAF synthesis, and as a result may act in a competition fashion with the enzyme involved in PAF synthesis. Hence, by blocking the iPLA 2 , a pool of membrane phospholipids may be exclusively hydrolyzed by the group V sPLA 2 leading to increased amount of lyso-PAF synthesized. This hypothesis is furthermore supported by the fact that these two enzymes do not demonstrate substrate selectivity, unlike cPLA 2 which prefers arachidonic acid-containing phospholipids. Finally, these data indicate as well that cPLA 2 is unlikely to take part in EC PAF production and evidence for this is starting to emerge. Indeed, several reports indicate that cPLA 2 is not involved in monocyte or neutrophil PAF biosynthesis but rather in prostanoid production (Leslie, 1997; Marshall et al., 1997; . As a result, this enzyme is most probably not implicated in EC PAF synthesis. In addition, this enzyme is active at low micromolar Ca
2+
, and we showed that at such concentrations VEGF did not induce the synthesis of PAF.
It is interesting to note that previous studies have shown that cPLA 2 activity is essential for the pro-in¯ammatory activity of group V sPLA 2 (Balsinde et al., 1998; Cho, 2000) . However, these studies investigate the implication of these two enzymes to prostaglandin synthesis. In contrast, we show that PAF synthesis mediated by group V sPLA 2 is independent of cPLA 2 activity. This is in agreement with a previous report that has also shown that PAF formation is dependent of sPLA 2 and independent of cPLA 2 (Marshall et al., 1999) , one might hypothesize that cPLA 2 activity is required for prostanoid synthesis, whereas cPLA 2 appears not to be implicated in PAF synthesis. This hypothesis is furthermore supported by a recent report in which it has been shown that group V sPLA 2 alone could mediate lyso-PAF synthesis (Murakami et al., 2001) .
In order to support the hypothesis that group V sPLA 2 mediates BAEC PAF synthesis, we then sought to determine if BAEC and HUVEC express a signi®cant amount of group IIA and/or V sPLA 2 enzymes. Western blot analysis indicated that both BAEC and HUVEC either stimulated or not with VEGF indeed express group V sPLA 2 and not group IIA sPLA 2 , thereby con®rming the possible involvement of group V sPLA 2 in PAF synthesis. Finally, group V sPLA 2 remained cell-associated and was not detected in the supernatant of BAEC and HUVEC challenged or not with VEGF. We con®rmed also by RT ± PCR the presence of group V sPLA 2 and the absence of group IIA sPLA 2 at least in HUVEC. Since our data support a direct role for group V sPLA 2 in VEGF-induced PAF synthesis in BAEC and that Western blot analysis clearly shows that BAEC express group V sPLA 2 , one might hypothesize that the discrepancy observed between Western blot and RT ± PCR analyses for BAEC expression of group V sPLA 2 may be rationalized by the fact that the oligonucleotides used for RT ± PCR were synthesized according to the human group V sPLA 2 cDNA sequences, since the bovine gene has not yet been sequenced. As a result, mismatches between bovine group V sPLA 2 mRNA and the RT ± PCR oligomers used might have been present. Nonetheless, our RT ± PCR experiments support the crucial role of group V sPLA 2 in HUVEC, and completely dissipates any possible ambiguity regarding a role of group IIA sPLA 2 in HUVEC PAF synthesis since this enzyme was not detected in HUVEC by Northern and Western blot analyses. Interestingly, others have shown that group IIA sPLA 2 expression is inducible by pro-in¯ammatory agents (Murakami et al., 1997) . Moreover, the fact that HUVEC do not express group IIA sPLA 2 and that the blockade of this enzyme by LY311727 (1 mM) did not reduce PAF synthesis con®rms that the inhibitory eect of the two speci®c inhibitors of groups IIA and V sPLA 2 , namely SB203347 and LY311727 (100 mM), on PAF synthesis induced by VEGF is not through the inhibition of group IIA sPLA 2 but rather through the inhibition of group V sPLA 2 .
VEGF and group V sPLA 2 Though group V sPLA 2 has been cloned only recently (Chen and Dennis, 1998) , a growing body of evidence has con®rmed that this novel enzyme is constitutively expressed mainly in the cardiovascular system (Chen et al., 1994) and is indeed an active eector in fatty acid metabolism. It was shown to take part in arachidonic acid-mediated signal transduction in macrophage-like cell line P388D 1 (Balboa et al., 1996) , as well as in eicosanoid formation in mast cells (Reddy et al., 1997) . Moreover, group V rather that group IIA as previously believed, is the primary 14 kDa PLA 2 synthesized by P388D 1 cells (Balboa et al., 1996) . In the present study, we demonstrate that this newly characterized enzyme is likely responsible for VEGF-induced PAF synthesis, that it is expressed in EC from both bovine aortas and human umbilical veins, and that it remains associated with the cells that were challenged with VEGF. This is in agreement with a recent report that has shown that group V sPLA 2 was cell associated and identi®ed intracellularly .
Previous investigations have proposed that an increase in microvascular permeability is a crucial step in angiogenesis associated with tumours and wounds (Connolly et al., 1989; Folkman & Klagsbrun, 1997) . According to this hypothesis, a major function of VEGF is probably the induction of plasma protein leakage. We have shown earlier that VEGFinduced protein extravasation was abolished by a PAF receptor antagonist in vivo (Sirois & Edelman, 1997) . Since this study supports the idea that group V sPLA 2 is responsible for the PAF synthesis mediated by VEGF and that diverse studies suggest that PAF acts as a proangiogenic factor (Camussi et al., 1995; Bussolino & Camussi, 1995; Montrucchio et al., 2000) , it would be of interest to investigate if the inhibition of this enzyme may interfere with VEGF in¯ammatory eect in vivo, as well as with its angiogenic potential.
In conclusion, our data showed that the production of PAF elicited by VEGF on BAEC and HUVEC is mediated by the activation of the remodelling pathway, and more speci®cally through the action of the group V sPLA 2 and lyso-PAF-AT. As the in¯ammatory reaction mediated by VEGF might be an essential key factor of angiogenesis, the inhibition of PAF synthesis mediated by VEGF might prevent the deleterious in¯ammation and angiogenesis imputable to VEGF overexpression in vivo.
